Post-PET Intended Management Stratified by NaF PET Findings in Patients with FOM
| Benign | Probable | Definitive | ||||||||||
| Finding | Breast | NSCLC | Other | Prostate | Breast | NSCLC | Other | Prostate | Breast | NSCLC | Other | Prostate |
| Scans (n) | 485 | 206 | 373 | 2,498 | 105 | 73 | 108 | 870 | 191 | 101 | 172 | 1,318 |
| Scans (%) | 13.6 | 5.8 | 10.5 | 70.1 | 9.1 | 6.3 | 9.3 | 75.3 | 10.7 | 5.7 | 9.7 | 74.0 |
| Post-PET intended management (%) | ||||||||||||
| Watch | 71.3 | 58.7 | 63.0 | 52.3 | 30.5 | 39.7 | 37.0 | 23.1 | 15.2 | 19.8 | 16.3 | 12.1 |
| Biopsy | 0.8 | 0.0 | 2.7 | 3.5 | 12.4 | 11.0 | 7.4 | 4.9 | 4.2 | 6.9 | 7.6 | 2.4 |
| Image | 12.4 | 11.7 | 9.1 | 6.4 | 23.8 | 13.7 | 22.2 | 15.5 | 23.0 | 18.8 | 11.6 | 7.0 |
| Any treatment | 15.5 | 29.6 | 25.2 | 37.8 | 33.3 | 35.6 | 33.3 | 56.4 | 57.6 | 54.5 | 64.5 | 78.5 |
| Treatment modalities* | ||||||||||||
| Hormones | 8.2 | 1.9 | 1.1 | 24.0 | 11.4 | 1.4 | 0.9 | 36.6 | 27.7 | 0.0 | 5.8 | 49.7 |
| Chemotherapy | 6.8 | 24.8 | 20.6 | 5.8 | 13.3 | 21.9 | 25.9 | 12.0 | 28.3 | 33.7 | 39.0 | 24.7 |
| Radiotherapy | 2.7 | 4.4 | 3.8 | 15.0 | 12.4 | 15.1 | 13.0 | 15.9 | 19.9 | 33.7 | 28.5 | 19.9 |
| Bisphosphonate | 1.2 | 2.9 | 1.3 | 4.3 | 16.2 | 12.3 | 9.3 | 16.7 | 27.2 | 10.9 | 20.9 | 29.3 |
↵* Referring physicians could select more than one treatment modality.
NSCLC = non–small cell lung cancer.